Eplontersen trial shows mixed heart benefit with combo therapy

A Nature Medicine secondary analysis of a phase 3 trial (NCT04136171) on Eplontersen for transthyretin amyloid cardiomyopathy found adding the drug improved nerve function but showed mixed results for heart health when patients were already on other stabilizers. The 144-patient study highlighted challenges in assessing new treatments for complex conditions, especially when layering therapies.